Biogen Inc (BIIB)
333.00
+0.13 +0.04%
NASDAQ
Feb 19, 16:59
Delayed 2m
USD
View All Key Stats
BIIB Key Stats
| Income Statement | |
| Revenue (TTM) | 13.45B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 21.62 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 4.431B |
| Profitability | |
| Gross Profit Margin (Quarterly) | 86.15% |
| Profit Margin (Quarterly) | 26.85% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 65.50B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 5.081 |
| PE Ratio (TTM) | 15.40 |
| Price to Book Value | 5.023 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | 1.670B |
| Return on Equity (TTM) | Upgrade |
View All BIIB News
BIIB News
-
WireHeadlineTime (ET)
-
SA Breaking News02/19 13:37
-
Yahoo02/19 10:22
-
Yahoo02/15 16:12
-
SA Breaking News02/15 10:48
-
Yahoo02/15 10:28
-
Yahoo02/14 18:08
-
MT Newswires02/14 14:22
-
Yahoo02/14 13:00
-
Yahoo02/14 10:08
-
SA Breaking News02/12 08:27
View All Events
BIIB Events
| Date | Type | Description |
|---|---|---|
| 04/24/2019 08:30 EDT | Misc | Biogen Inc First Quarter Earnings Conference Call in 2019 |
| 04/24/2019 | Earnings | Biogen Inc First Quarter Earnings Results in 2019 |
| 02/06/2019 | Misc | Biogen Inc Annual Report in 2018 |
| 01/29/2019 08:00 EST | Misc | Biogen Inc Fourth Quarter Earnings Conference Call in 2018 |
| 01/29/2019 | Earnings | Biogen Inc Fourth Quarter Earnings Results in 2018 |
| 10/23/2018 08:00 EDT | Misc | Biogen Inc Third Quarter Earnings Conference Call in 2018 |
| 10/23/2018 | Earnings | Biogen Inc Third Quarter Earnings Results in 2018 |
| 07/24/2018 08:00 EDT | Misc | Biogen Inc Second Quarter Earnings Conference Call in 2018 |
| 07/24/2018 | Earnings | Biogen Inc Second Quarter Earnings Results in 2018 |
| 06/12/2018 | Misc | Biogen Inc Annual General Meeting in 2017 |
BIIB Fundamentals
Income Statement View Statement
BIIB Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
BIIB One Page Reports
- One Page Report Download
BIIB Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 333.00 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Edit
Profile
- URL: http://www.biogen.com
- Investor Relations URL: https://www.biogen.com/en_us/investors.html
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Equity Style: Large Cap/Blend
- Next Earnings Release: Apr. 24, 2019
- Last Earnings Release: Jan. 29, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
BIIB Excel Add-In Codes
- Name: =YCI("BIIB","name")
- Description: =YCI("BIIB","description")
- Sector: =YCI("BIIB","sector")
- Industry: =YCI("BIIB","industry")
- Est. Current Fiscal Year End: =YCI("BIIB","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other BIIB Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BIIB Tweets Stocktwits
Advertisement
